0HI3 Stock Chart & Stats
$86.14
-$2.42(-2.81%)
At close: 4:00 PM EDT
$86.14
-$2.42(-2.81%)
Day’s Range― - ―
52-Week Range$19.58 - $95.49
Previous CloseN/A
Volume1.14K
Average Volume (3M)1.90K
Market Cap
$12.42B
Enterprise Value$11.46K
Total Cash (Recent Filing)$1.60B
Total Debt (Recent Filing)$864.07M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Nov 30, 2026EPS Estimate
-1.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.24
Shares Outstanding141,254,470
10 Day Avg. Volume2,518
30 Day Avg. Volume1,904
Financial Highlights & Ratios
PEG Ratio28.34
Price to Book (P/B)9.90
Price to Sales (P/S)5.56
P/FCF Ratio29.41
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$109.76Price Target Upside27.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.19
Revenue Forecast (FY)$459.46M
Bulls Say, Bears Say
Bulls Say
Pivotal Phase III EfficacyDurable clinical differentiation from two positive pivotal trials materially de-risks regulatory and reimbursement paths. Deep, consistent triglyceride reductions and major acute pancreatitis event reductions support long-term therapeutic value, stronger payer negotiations, and sustained market positioning versus incremental competitors.
Strong Liquidity RunwayA sizable cash/investment balance provides multi-quarter runway to complete late‑stage programs, fund commercialization scale-up, and execute strategic moves (e.g., priority review voucher). That financial flexibility lowers short‑term funding risk and enables deliberate investment in durable value drivers.
Partnership-driven Revenue GrowthRobust collaboration and milestone income diversifies cash sources and validates Arrowhead's platform. Partner funding and licensing reduce reliance on early product sales, sustain R&D funding, and create non‑dilutive financing that supports long‑term pipeline advancement and commercial readiness.
Bears Say
Persisting UnprofitabilitySustained large operating losses constrain return generation and increase dependency on external capital or collaboration receipts. Continued negative profitability over the medium term limits reinvestment capacity, magnifies dilution or debt risk if cash burn persists, and pressures long‑term ROE.
Volatile And Negative Cash FlowUneven cash conversion creates funding unpredictability; while 2025 showed positive cash flow, the TTM negatives signal reliance on irregular milestone receipts. Persistent volatility raises the probability of future financing needs and complicates sustained commercial investment and pipeline progression.
Early Commercial Ramp And Payer UncertaintyInitial launch traction is encouraging but product sales remain immaterial. Long‑term uptake depends on extensive physician/payer education, contracting outcomes, and competition; slow adoption or reimbursement setbacks would delay durable revenue generation and strain the funding model tied to commercialization timing.
Arrowhead Pharmaceuticals News
0HI3 FAQ
What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
Arrowhead Pharmaceuticals lowest share price was $19.58 and its highest was $95.49 in the past 12 months.
What is Arrowhead Pharmaceuticals’s market cap?
Arrowhead Pharmaceuticals’s market cap is $12.42B.
When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
Arrowhead Pharmaceuticals’s upcoming earnings report date is Nov 30, 2026 which is in 102 days.
How were Arrowhead Pharmaceuticals’s earnings last quarter?
Arrowhead Pharmaceuticals released its earnings results on Aug 04, 2026. The company reported -$1.36 earnings per share for the quarter, missing the consensus estimate of -$1.277 by -$0.083.
Is Arrowhead Pharmaceuticals overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals pay dividends?
Arrowhead Pharmaceuticals does not currently pay dividends.
What is Arrowhead Pharmaceuticals’s EPS estimate?
Arrowhead Pharmaceuticals’s EPS estimate is -1.53.
How many shares outstanding does Arrowhead Pharmaceuticals have?
Arrowhead Pharmaceuticals has 141,254,470 shares outstanding.
What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
Arrowhead Pharmaceuticals reported an EPS of -$1.36 in its last earnings report, missing expectations of -$1.277. Following the earnings report the stock price went down -0.079%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
Currently, no hedge funds are holding shares in GB:0HI3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arrowhead Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$109.76 (27.42% Upside)
$109.76 (27.42% Upside)
Blogger Sentiment
Bullish
GB:0HI3 Sentiment 75%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
443.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
52.98%
Trailing 12-Months
Company Description
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
0HI3 Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was decidedly positive on clinical and strategic fronts: landmark Phase III SHASTA-3/4 results (deep TG reductions and major reductions in acute pancreatitis), broad regulatory approvals, accelerating commercial traction in FCS, strong partnership revenue and a robust pipeline with multiple near-term data catalysts. Offsetting items include increased net losses and higher operating spend as Arrowhead scales R&D and commercial infrastructure, a sizable near-term cash payment for a priority review voucher ($215M), and the fact that commercial product revenues remain small today. Overall, management portrayed the financial investments as deliberate and tied to significant near-term derisking and value-creation events.View all GB:0HI3 earnings summaries0HI3 Stock 12 Month Forecast
Average Price Target
$109.76
▲(27.42% Upside)